In search of treatment for tardive dyskinesia: review of the literature

Schizophrenia Bulletin
Dilip V Jeste, R J Wyatt


Studies on the treatments for neuroleptic-induced tardive dyskinesia published in the English literature until August 1978 are reviewed. There is a yet no single satisfactory method of treatment for tardive dyskinesia. Withdrawal of neuroleptics results in a remission of symptoms in younger and non-brain-damaged patients. Paradoxically, the most effective treatment for suppressing dyskinesia is administration of neuroleptics. The possibility that continued use of neuroleptics in dyskinesia patients produces irreversible brain damage remains to be validated (or invalidated). Anticholinergic and dopaminergic drugs are of no value in the treatment of tardive dyskinesia. Cholinergic drugs have not lived up to their initial promising results in this condition. About one third of the dyskinetic subjects seem to respond to various nonspecific measures. Tardive dyskinesia probably consists of at least two subtypes-- reversible and persistent. Methodological aspects of earlier studies and possibilities for future research in this field are discussed. Suggestions for treatment of individual cases are also outlined.


Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·N M RupniakS D Iversen
Jan 1, 1983·Psychopharmacology·B WistedtA Jørgensen
Jan 1, 1985·Psychopharmacology·W M GlazerM Roffman
Jan 1, 1982·Psychopharmacology·H A NasrallahM McCalley-Whitters
Jan 1, 1995·Journal of Neural Transmission. General Section·T KakigiC A Tamminga
Jun 1, 1988·Biological Psychiatry·S P MahadikS E Karpiak
Oct 1, 1986·Pharmacology, Biochemistry, and Behavior·L M GunneP Johansson
Jun 1, 1981·Psychiatry Research·Dilip V JesteR J Wyatt
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Wolfarth, K Ossowska
Aug 1, 1983·Brain Research Bulletin·R E Becker, H Lal
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
May 1, 1982·Psychological Medicine·S C RastogiA C Gibson
May 23, 2002·Clinical Neuropharmacology·Robert L Rodnitzky
Feb 16, 2005·Expert Opinion on Drug Safety·Robert L Rodnitzky
Nov 1, 1986·Acta Psychiatrica Scandinavica·S D SoniG Sampath
Jun 6, 2003·Seminars in Pediatric Neurology·Robert L Rodnitzky
Jan 1, 1985·Folia Psychiatrica Et Neurologica Japonica·K KashiharaS Otsuki
Apr 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·G G Fisk, S M York
Aug 16, 2003·Journal of Clinical Psychopharmacology·Verinder Sharma
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·S S WeberP Mastrati
Feb 1, 1988·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·M W WatsonF Jamali
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable

Related Concepts

Brain Injuries
Antipsychotic Effect
Cholinergic Agents
Neuroleptic Malignant Syndrome
Dopaminergic Agents
Research Methodology
Administration Procedure
Tardive Dyskinesia

Related Feeds

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.